Eurocine and Redbiotec partner to develop HSV-2 vaccines
Redbiotec is entitled to receive royalty payments on Eurocine’s net sales of an approved HSV-2 vaccine.

Redbiotec is entitled to receive royalty payments on Eurocine’s net sales of an approved HSV-2 vaccine.
The parties will assess the in vivo effects of SFX-01 in models of colorectal cancer.
The process development teams of the companies will work together in a GMP facility of ABL in Lyon, France.
Pfizer will gain rights to ReViral’s portfolio of therapeutic candidates, including sisunatovir.
Debt offerings in the pharma sector have seen a decrease of 34.7% from H2 2020 to H2 2021, an analysis…
ByTop-line data from Phase II Target-HTN trial of MLS-101 in patients with uncontrolled hypertension is expected this year.
The alliance will merge Integral Molecular’s antibody discovery and mRNA immunisation expertise with Optimeos’ technology.
Zydis technology produces a freeze-dried tablet that dissolves quickly in the mouth without needing water.
Thank you for subscribing to Pharmaceutical Technology